82 related articles for article (PubMed ID: 33765613)
1. Expression of PD-L1 in EBV-associated malignancies.
Li X; Zhang W
Int Immunopharmacol; 2021 Jun; 95():107553. PubMed ID: 33765613
[TBL] [Abstract][Full Text] [Related]
2. EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
Serafini B; Benincasa L; Rosicarelli B; Aloisi F
J Neuroimmunol; 2024 Apr; 389():578314. PubMed ID: 38422689
[TBL] [Abstract][Full Text] [Related]
3. Regulatory mechanisms of PD-L1 expression in cancer cells.
Shi Y
Cancer Immunol Immunother; 2018 Oct; 67(10):1481-1489. PubMed ID: 30120503
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus and PD-L1 in Esophageal and Esophagogastric Junction Cancer: Differences According to Location and Histological Type.
Ribeiro MB; Marques SB; Soares IC; Pereira MA; Takeda FR; Safatle-Ribeiro AV; Ribeiro U
J Gastrointest Surg; 2022 Nov; 26(11):2358-2364. PubMed ID: 35668227
[No Abstract] [Full Text] [Related]
5. Immune checkpoint inhibitors in the treatment of virus-associated cancers.
Gao P; Lazare C; Cao C; Meng Y; Wu P; Zhi W; Lin S; Wei J; Huang X; Xi L; Chen G; Hu J; Ma D; Wu P
J Hematol Oncol; 2019 Jun; 12(1):58. PubMed ID: 31182108
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Apolipoprotein L6 Improves Tumor Immunotherapy by Inducing Immunogenic Cell Death.
Liu K; Chen Y; Li B; Li Y; Liang X; Lin H; Luo L; Chen T; Dai Y; Pang W; Zeng L
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979348
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus: From kisses to cancer, an ingenious immune evader.
Trivedi P; Slack FJ; Anastasiadou E
Oncotarget; 2018 Nov; 9(92):36411-36412. PubMed ID: 30559926
[No Abstract] [Full Text] [Related]
8. Hyperprogressive disease: a distinct effect of immunotherapy?
Popat V; Gerber DE
J Thorac Dis; 2019 Mar; 11(Suppl 3):S262-S265. PubMed ID: 30997192
[No Abstract] [Full Text] [Related]
9. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.
Yoshimori M; Shibayama H; Imadome KI; Kawano F; Ohashi A; Nishio M; Shimizu N; Kurata M; Fujiwara S; Arai A
Blood Adv; 2021 Apr; 5(7):1805-1815. PubMed ID: 33787860
[TBL] [Abstract][Full Text] [Related]
10. The immune escape mechanism of nasopharyngeal carcinoma.
Li X; Guo Y; Xiao M; Zhang W
FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
[TBL] [Abstract][Full Text] [Related]
11. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.
Wang J; Ge J; Wang Y; Xiong F; Guo J; Jiang X; Zhang L; Deng X; Gong Z; Zhang S; Yan Q; He Y; Li X; Shi L; Guo C; Wang F; Li Z; Zhou M; Xiang B; Li Y; Xiong W; Zeng Z
Nat Commun; 2022 Feb; 13(1):866. PubMed ID: 35165282
[TBL] [Abstract][Full Text] [Related]
12. Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation.
Ohsawa K; Momose S; Nishikori A; Nishimura MF; Gion Y; Sawada K; Higashi M; Tokuhira M; Tamaru JI; Sato Y
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610976
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants.
Wu C; Ke Y; Wan L; Xie X
Cancer Immunol Immunother; 2024 Mar; 73(5):79. PubMed ID: 38554165
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive pyothorax-associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3.
Higuchi T; Hashida Y; Matsuo K; Kitahata K; Ujihara T; Murakami I; Nakayama T; Daibata M
Cancer Sci; 2023 Jun; 114(6):2622-2633. PubMed ID: 36898851
[TBL] [Abstract][Full Text] [Related]
15. EBV dUTPase: A Novel Modulator of Inflammation and the Tumor Microenvironment in EBV-Associated Malignancies.
Williams MV; Mena-Palomo I; Cox B; Ariza ME
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765813
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.
Zhou N; Tang H; Yu S; Lin Y; Wang Y; Wang Y
Front Immunol; 2022; 13():1001414. PubMed ID: 36561745
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 is upregulated in CD163+ tonsillar macrophages from children undergoing EBV primary infection.
Moyano A; Ferressini N; De Matteo E; Preciado MV; Chabay P
Front Immunol; 2022; 13():940910. PubMed ID: 36451810
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the first PD-1 ligand encoded by a pathogen.
MartÃnez-Vicente P; Poblador F; Leitner J; Farré D; Steinberger P; Engel P; Angulo A
Front Immunol; 2022; 13():1007334. PubMed ID: 36177035
[TBL] [Abstract][Full Text] [Related]
19. Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.
Zhang WT; Zhu GL; Xu WQ; Zhang W; Wang HZ; Wang YB; Li YX
Diagn Pathol; 2022 Jul; 17(1):61. PubMed ID: 35842661
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.
Zheng X; Huang Y; Li K; Luo R; Cai M; Yun J
Viruses; 2022 May; 14(5):. PubMed ID: 35632758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
